Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa

► This extension study continued Late-Onset Treatment Study (LOTS) out to 104 weeks. ► Patients maintained the improved walking distance at 104 weeks. ► Patients maintained stabilization in pulmonary function at 104 weeks. ► Treatment-related AEs were mainly infusion-associated reactions (35% of patients). ► No deaths or anaphylactic reactions were observed.